Dendritic cell immunotherapy for glioblastoma

Stavros Polyzoidis1, Keyoumars Ashkan

  • 1Department of Neurosurgery, King's College Hospital, Denmark Hill London, SE5 9RS, UK.

Dendritic cell immunotherapy is emerging as a promising addition to the multimodal treatment of patients with glioblastoma multiform. Initial Phase I and II trials have demonstrated favorable outcomes with minimal toxicity. In this editorial, the current status and the future challenges of this therapy are discussed.

Related Concept Videos